Pancreatic Enzyme

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Short Bowel Syndrome

Conditions

Short Bowel Syndrome

Trial Timeline

Mar 24, 2017 → Feb 1, 2019

NCT ID

NCT03097029

About Pancreatic Enzyme

Pancreatic Enzyme is a phase 2 stage product being developed by AbbVie for Short Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03097029. Target conditions include Short Bowel Syndrome.

What happened to similar drugs?

5 of 15 similar drugs in Short Bowel Syndrome were approved

Approved (5) Terminated (2) Active (10)

✅Growth HormoneEli LillyApproved

✅Somatotropin growth hormone recombinant humanPfizerApproved

✅Genotropin (somatropin)PfizerApproved

✅GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved

✅Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved

🔄somatropin + leuprorelinEli LillyPhase 3

🔄Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03097029	Phase 2	Completed	Mar 24, 2017	Feb 1, 2019	Short Bowel Syndrome

Competing Products

20 competing products in Short Bowel Syndrome

See all competitors

Product	Company	Stage	Hype Score
somatropin + leuprorelin	Eli Lilly	Phase 3	40
Growth Hormone	Eli Lilly	Approved	35
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone	AstraZeneca	Phase 3	40
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)	Merck	Phase 1	29
Saizen® + Saizen®	Merck	Phase 3	40
r-metHuLeptin	Amgen	Phase 1	29
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Somatotropin growth hormone recombinant human	Pfizer	Approved	43
Genotropin (somatropin)	Pfizer	Approved	43
Genotropin + Genotropin	Pfizer	Phase 3	40
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment	Pfizer	Approved	43
Genotropin	Pfizer	Phase 2/3	38
glepaglutide	Zealand Pharma	Phase 3	41
Glepaglutide	Zealand Pharma	Phase 3	41
ZP1848	Zealand Pharma	Phase 2	32
glepaglutide + Placebo	Zealand Pharma	Phase 3	37
Glepaglutide	Zealand Pharma	Phase 3	37
Glepaglutide 10 mg	Zealand Pharma	Phase 3	44
Glepaglutide	Zealand Pharma	Phase 3	44
Nutropin [Somatropin (rDNA origin) for injection]	Ipsen	Approved	32